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Recurrent chromosome aberrations are frequently observed in human neoplastic cells and often correlate with other clinical and
histopathological parameters of a given tumour type. The clinical presentation, histology and biology of many canine cancers closely
parallels those of human malignancies. Since humans and dogs demonstrate extensive genome homology and share the same
environment, it is expected that many canine cancers will also be associated with recurrent chromosome aberrations. To investigate
this, we have performed molecular cytogenetic analyses on 25 cases of canine multicentric lymphoma. Comparative genomic
hybridisation analysis demonstrated between one and 12 separate regions of chromosomal gain or loss within each case, involving 32
of the 38 canine autosomes. Genomic gains were almost twice as common as losses. Gain of dog chromosome (CFA) 13 was the
most common aberration observed (12 of 25 cases), followed by gain of CFA 31 (eight cases) and loss of CFA 14 (five cases).
Cytogenetic and histopathological data for each case are presented, and cytogenetic similarities with human non-Hodgkin’s
lymphoma are discussed. We have also assembled a panel of 41 canine chromosome-specific BAC probes that may be used for
accurate and efficient chromosome identification in future studies of this nature.
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Malignant lymphoma (lymphosarcoma) represents one of the most
frequently encountered canine neoplasms, most commonly affect-
ing middle-aged to older dogs of a wide range of breeds (Greenlee
et al, 1990 and others). The disease originates from the malignant
transformation of developing lymphocytes, and in the absence of
chemotherapy, survival beyond one month after diagnosis is
uncommon (MacEwan, 1990). Although generally considered a
chemoresponsive form of malignancy in the dog, it is clear that, as
with human non-Hodgkin’s lymphoma (NHL), the disease is
highly heterogeneous at both the clinical and histological level. A
proportion of cases demonstrate more favourable response to
therapy, and longer overall survival time, than others receiving the
same initial diagnosis (Teske et al, 1994a).
A limited number of diagnostic and prognostic indicators have
been described that may aid in the clinical management of canine
lymphoma (e.g. Greenlee et al, 1990; Kuipel et al, 1999; Dobson
et al, 2001), but it is evident that additional such aids are required
in order to generate more refined modes of subclassification.
Coupled with their physiological comparability, extensive genome
homology, shared environment and the similarity in their clinical
presentation of the disease, the domestic dog (Canis familiaris,
CFA) represents an ideal system in which to study human
multicentric lymphoma. As with many other human cancers,
NHL is associated with a range of nonrandom chromosome
aberrations (reviewed by Gaidano et al, 1993, Johansson et al,
1995; Sarris and Ford 1999 and others), a proportion of which has
been shown to correlate with the clinical subtype of the disease.
More recently, Alizadeh et al (2000) demonstrated the existence of
marked variation in genome-wide gene expression profiles
generated for human lymphoma patients who received a similar
diagnosis. These factors represent potentially invaluable ap-
proaches to refining disease subclassification and assisting clinical
diagnosis, prognosis and case management.
Since humans and dogs demonstrate extensive genome homol-
ogy, it is likely that canine lymphoma will also be associated with
recurrent chromosome aberrations. However, few reports exist
describing chromosome abnormalities detected in canine lympho-
ma and at present insufficient data are available from which to
draw significant conclusions on their findings. The most extensive
study of this kind in the dog to date (Hahn et al, 1994) used
conventional cytogenetic techniques to identify the single most Received 3 January 2003; revised 4 June 2003; accepted 22 July 2003
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scommonly occurring aberration in chromosome preparations
generated from each of 61 canine lymphoma cases. Of these,
70% demonstrated genomic imbalance as a consequence of
aneuploidy (43 out of 61 cases), while balanced translocations
were identified in the remaining 30% (18 out of 61 cases),
identifying several potential trends that warrant further investiga-
tion. Studies of this kind, however, have been limited by difficulties
in achieving accurate and consistent chromosome identification in
the domestic dog, whose karyotype is notable for its high diploid
chromosome number (2n¼78), and the similar size, morphology
and banding patterns of many of the autosomes, all of which are
acrocentric. In addition, the reduced quality of chromosome
preparations typically generated from tumour material further
compound the practical limitations of a highly time-consuming
purely classical approach.
The development of comparative genomic hybridisation (CGH)
(Kallioniemi et al, 1992, 1994) as a technique for indirect analysis
of chromosomal copy number changes in human tumour cells now
provides a means by which imbalanced genomic aberrations can
be identified accurately and efficiently without the need to generate
tumour chromosome preparations. The application of CGH to the
dog (Dunn et al, 2000; Thomas et al, 2001), the advent of novel
molecular cytogenetic resources for this species (Langford et al,
1996), the development of comparative cytogenetic maps (Breen
et al, 1999a, 2001; Yang et al, 1999; Sargan et al, 2000) and the
generation of an integrated canine genome map (Breen et al, 2001)
now provide a means by which to overcome prior practical
difficulties and embark on more comprehensive studies of tumour
karyotypes in this species. In addition to expanding our knowledge
of the canine disease, the resulting comparative data will enable
improved correlation between human and canine counterparts of a
given cancer where they exist.
We have used CGH analysis to identify chromosome imbalances
in 25 cases of canine multicentric lymphoma. The resulting range
and distribution of aberrations observed indicates that, as with the
human counterpart of this disease, the cytogenetic profiling of
canine lymphoma as a potential aid to diagnosis and clinical
management warrants more detailed investigation.
MATERIALS AND METHODS
Collection of case material
The 25 canine lymphoma cases described in this report were
recruited from primary care veterinary practices throughout the
UK during 1999–2001. Tumours represented suspected cases of
multicentric malignant lymphoma on the basis of generalised
lymphadenopathy, and the diagnosis was subsequently confirmed
for each case by histological evaluation. The age at diagnosis
ranged from 1 to 12 years (mean 8 years), and comprised 14
females and 11 males, of 12 different breeds (Table 1).
Following surgical excision, biopsied lymph node material was
bisected and DNA was extracted from a representative region of
tissue as described below. The remainder was collected into
formalin for histological analysis. All biopsy procedures were
performed prior to initiation of steroid treatment or chemotherapy.
Histological and immunophenotyping analyses
Histological analysis and immunophenotyping of biopsied lymph
node material was carried out using routine processing methods as
previously described (Thomas et al, 2001), with the exception that
tissue sections were immunolabelled using an indirect immuno-
peroxidase technique. Using the Techmate Horizon immunostain-
ing apparatus (DAKO) according to the manufacturer’s
instructions, two sections were incubated in the primary antiserum
for 1h at room temperature. Anti-CD3 (pan T-cell marker) and
anti-CD79a (pan B-cell marker) were diluted in DAKO antibody
diluent to 1:400 and 1:100, respectively. Negative controls were
generated by incubating two additional sections in diluent only,
but mirrored all sequential steps of the two positive sections.
Positive controls were provided by labelling sections of normal
canine lymph node in parallel with the test sections. After washing
for 10min in DAKO buffer, sections were incubated for a further
hour in rabbit/mouse EnVision (DAKO) conjugated to horseradish
peroxidase. Tissue sections were then stained, mounted and
examined as previously described (Thomas et al, 2001). Cases
were classified by cell morphology and immunophenotype
according to both the Working Formulation (National Cancer
Institute, 1982) and the Kiel classification system (Lennert, 1978;
Lennert and Feller, 1990).
Tumour DNA extraction and probe labelling
Isolation of DNA from biopsied tumour material was performed as
previously described (Thomas et al, 2001). Haematoxylin/eosin-
stained sections were examined to establish that each specimen
contained minimal (o10%) non-tumour tissue. DNA was also
isolated from the peripheral blood lymphocytes of clinically
normal male and female donors using the same method. Previous
CGH analyses using DNA from these donors did not detect any
statistically significant chromosome imbalances within either
individual (Dunn et al, 2000). One microgram of tumour (test)
and 1mg of normal (reference) DNA were labelled separately by
incorporation of Spectrum Green- and Spectrum Red-dUTP (Vysis
Illinois, USA), respectively, in a standard nick translation reaction
in which the DNase I concentration was adjusted to result in the
generation of fragments ranging from 100 to 1000bp. The
differentially labelled test and reference probes were then
combined in the presence of canine Cot-1 competitor DNA,
ethanol-precipitated and resuspended in hybridisation buffer as
described by Dunn et al (2000).
Image acquisition and CGH analysis
Fluorescence in situ hybridisation (FISH) and CGH analysis was
performed as previously described (Dunn et al, 2000; Thomas et al,
2001). A minimum of 10 metaphase chromosome spreads, of
comparable length and with minimal overlaps, were analysed
individually using the QUIPS CGH analysis package (Vysis) to
generate a relative copy number karyotype. Fluorescence profiles,
representing the ratio of test:reference DNA, were plotted along
the length of each chromosome against the corresponding DAPI-
banded ideogram (Breen et al, 1999b). Profiles from individual
metaphase spreads were then merged using the QUIPS CGH
interpretation package (Vysis) to generate a mean fluorescence
profile for each chromosome.
Confirmation of chromosome identity
Chromosome imbalances detected by CGH analysis were identified
by linear enhancement of the inverted DAPI component of each
captured image, and comparison with the DAPI-banded dog
karyotype of Breen et al (1999b). Where necessary, their identity
and orientation was further verified using a panel of canine
chromosome-specific single locus FISH probes (SLPs). This panel
comprises 41 canine BAC clones, selected from the canine BAC
library RPCI-81 (Li et al, 1999) on the basis of their cytogenetic
position, as illustrated in Figure 1. DNA was isolated from the
panel of BAC clones using a standard alkaline lysis method, and
1mg of each was labelled for FISH analysis by standard nick
translation to incorporate either diethylaminomethylcoumarin
(DEAC)-5-dUTP (NEN), Spectrum Orange-dUTP (Vysis) or
biotin-16-dUTP (Boehringer Mannheim, Germany). Use of these
fluorochromes prevented spectral overlap with those used in CGH
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clones were selected on the basis of their cytogenetic location being
in a centromeric, central or telomeric position (Figure 1).
Consequently, the combination of fluorochrome and cytogenetic
position allows multiple chromosomes to be identified in a single
FISH reaction. Metaphase preparations analysed by CGH analysis
were redenatured and exposed to additional rounds of FISH
analysis using groups of differentially labelled SLPs (20ng each) in
the presence of 10mg of sonicated dog genomic DNA as
competitor. Biotinylated probes were detected with Cy5-conju-
gated avidin (4mgml
 1, Amersham Pharmacia, Bucks, UK).
Images for the same metaphase spreads acquired in the successive
rounds of FISH analysis were compared with the original CGH
image in order to confirm chromosome identity.
RESULTS
Histopathological evaluation and immunostaining
Of the 25 canine lymphoma cases analysed, 20 (80%) were of B-cell
origin, and four (16%) were of T-cell origin. The remaining case
demonstrated coexpression of both T- and B-cell antigens and has
been described in detail elsewhere (Thomas et al, 2001). The panel
comprised approximately equal numbers of low-grade (11 out of
25, 44%) and high-grade (14 out of 25, 56%) lymphomas. The
predominance of B-cell lymphomas is broadly in line with
previous reports, and with case numbers submitted for routine
diagnostic evaluation from UK practices (data not shown), as is the
slight predominance of high-grade over low-grade lymphomas. Six
morphological subtypes were identified in total, with between one
and nine representatives of each subtype.
CGH analysis
An example of CGH analysis, and subsequent reprobing of the
same metaphase for confirmation of chromosome identification, is
presented in Figure 2. Unbalanced chromosome aberrations were
classed as those regions demonstrating a test:reference fluores-
cence ratio greater than 1.15:1 (gain) or less than 0.85:1 (loss),
following standard conventions. Instances where a site of either
gain or loss was interrupted by a short region falling marginally
inside this range (and therefore not displaying statistically
Table 1 Summary of histopathological and cytogenetic data for 25 dog lymphoma cases
Case no. Sex/age Breed
Classification (working
formulation)
Classification
(Kiel)
Immunophenotype/
grade Chromosome aberrations
3971/01 ~/10 WHWT Diffuse, small cell Lymphocytic B/low +13
0882/01 #/10 Border collie Diffuse, small lymphocytic Lymphoplasmacytic B/low +10/+27
3624/00 ~/6 X-breed Diffuse, small lymphocytic Lymphoplasmacytic B/low +1/ 24qprox/ 33/ 36qprox
1354/00 ~/11 X-breed Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
B/low +31
3718/00 #/5 Lurcher Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
B/low  14/+35
4033/00 ~/11 GSD Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
B/low  3qprox/+3qdist/ 14
4757/00 ~/4 EBT Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
B/low +13/+31
1996/01 #/10 Golden retriever Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
B/low +13/ 14
4942/00 #/7 Bull mastiff Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
B/low +13
4775/00 #/8 X-breed Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
T/low  7qprox/+12/+13/ 22/ 23/+36/+38
4432/01 ~/6 Boxer Diffuse, mixed, small and
large cell
Centroblastic-
centrocytic
T/low +12/+13/+21qdist/+31/+36qdist/+37
1218/01 ~/9 Cocker spaniel Diffuse, lymphoblastic Lymphoblastic B/high  14/+27
3280/98 #/9 X-breed Diffuse, lymphoblastic Lymphoblastic B+T/high  11/ 30/+36/ 38
4318/00 #/8 Cocker spaniel Diffuse, lymphoblastic Lymphoblastic T/high +1/+6/ 11/+20qprox/ 28/+29/
+30qprox/ 30qdist/+31qdist/ 34qdist/
 38qdist
1947/01 ~/12 Cocker spaniel Diffuse, lymphoblastic Lymphoblastic T/high +4qprox-qmid/+6qprox/ 8qprox/
+9qdist/
 11qdist/ 16qdist/ 19/ 25/ 33/+35/
+36/ 38
1935/99 ~/11 GSD Diffuse, large cell Centroblastic B/high +31
0233/00 ~/9 Boxer Diffuse, large cell Centroblastic B/high +31
2386/00 #/9 X-breed Diffuse, large cell Centroblastic B/high +13/ 22
4115/00 ~/9 Lurcher Diffuse, large cell Centroblastic B/high +13/+18
4517/00 #/8 CKCP Diffuse, large cell Centroblastic B/high +31
0018/01 #/1 Border collie Diffuse, large cell Centroblastic B/high +1/+13
1265/01 ~/8 Standard poodle Diffuse, large cell Centroblastic B/high +13/+16
1600/01 ~/6 Golden retriever Diffuse, large cell Centroblastic B/high  14
4290/01 #/10 X-breed Diffuse, large cell Centroblastic B/high +13/+14qdist/+31
4641/00 ~/6 Bull mastiff Diffuse, immunoblastic Immunoblastic B/high +13
Case reference numbers are followed by the sex and age of the patient (in years), and the breed. Breed abbreviations are: West Highland white terrier (WHWT); German
shepherd dog (GSD); English bull terrier (EBT); cavalier King Charles spaniel (CKCP). The classification of each case using both the Kiel and Working Formulation systems is then
given, followed by the immunophenotype and grade of the case. The final column summarises the cytogenetic data for each case, and represents a brief list of the aberrations
detected. The precise subchromosomal extent of each aberration is shown in Figure 3.
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of CFA 1 in case 0018/01; gain of CFA 6 in 4318/00; gain of CFA 13
in cases 1196/01, 4115/00 and 0018/01; loss of CFA 16 in 1947/01;
loss of CFA 24 in 3624/00).
At least one unbalanced chromosome aberration was detected in
each of the 25 cases studied, with a maximum of 12 aberrations
detected in a single case (case 1947/01). In total, 76 aberrations
were identified throughout the panel, equivalent to a mean of three
per case. Of these, gains (48 out of 76, 63.8%) were significantly
more common than losses (28 out of 76, 36.8%). Allowing for the
convention of excluding centromeric and telomeric regions from
CGH analysis, the majority of imbalances (59 of 76, 77.6%) were
extensive, involving half or more of the physical length of the
chromosome. Aberrations involved 32 of the 38 dog autosomes,
with only CFA 2, 5, 15, 17, 26 and 32 demonstrating no detectable
imbalance within any of the 25 lymphoma cases. Of these 32
autosomes, 16 (50%) showed only a single detectable instance of
either over- or under-representation within the panel. The most
common aberration detected was gain of CFA 13, present in 12 of
the 25 cases (48%), followed by gain of CFA 31 in eight cases
(32%). The most frequent losses were of CFA 14 (five of 25 cases,
20%), and of CFA 11 (three of 25 cases, 12%). It was most
commonly observed that any given autosome demonstrated either
gains or losses, with only six chromosomes (CFA 3, 14, 16, 30, 36
and 38) demonstrating at least one incidence of both over- and
under-representation within the panel as a whole. In two instances
(CFA 3 in case 4033/00; CFA 30 in case 4318/00), separate regions
of both gain and loss were identified along the length of the same
chromosome.
Patient details, and histopathological and cytogenetic data are
summarised in Table 1. Figure 3 presents the compiled CGH data
obtained for each of the 25 cases analysed, showing the precise
physical extent of each region of imbalance.
DISCUSSION
CGH analysis of the 25 canine lymphomas demonstrated a total of
76 instances of significant genomic imbalance. The most striking
trend observed was the gain of CFA 13 in almost half of the cases
studied (12 of 25, 48%). This correlates with the findings of Hahn
et al (1994), who reported trisomy of CFA 13 as the most common
unbalanced aberration identified in their panel of cases studied by
conventional cytogenetics (15 of 61 cases, 24.6%). Interestingly, the
authors suggested a direct correlation between the existence of
trisomy CFA 13 and an increase in both first remission length and
survival time. In the present study, gain of CFA 13 was found in
four of the six morphological subgroups of lymphoma identified,
being absent in both lymphoplasmacytic and lymphoblastic
lymphomas (see Table 1). Comparative mapping studies using
reciprocal chromosome painting (Breen et al, 1999a; Yang et al,
1999) and radiation-hybrid mapping (Breen et al, 2001) show that
CFA 13 is evolutionarily related to sites on two human
chromosomes, HSA 8q23-qtel and HSA 4pprox-qprox. The former
of these human chromosome sites harbours the c-myc oncogene,
and the latter the c-KIT oncogene. Activation of human c-myc has
been shown to be a common event in intermediate- and high-grade
NHL (Gaidano et al, 1993) and so the recurrent gain of CFA 13
observed in this study suggests that it is crucial to examine the
potential involvement of c-MYC and c-KIT in canine tumour
development.
Of the other common aberrations observed in this study, gain of
CFA 31 (eight of 25 cases) was largely restricted to centroblastic
and centroblastic–centrocytic lymphomas. CFA 31 shares con-
served synteny with HSA 21 (Breen et al, 1999a; Yang et al, 1999).
Although aberrations of HSA 21 do not appear to be common in
human lymphoma, HSA 21 amplification is frequently in a number
of other cancers (e.g. Cortes et al, 1995; Perkins et al, 1997;
Loncarevic et al, 1999). The overabundance of genetic material
associated with disorders resulting from trisomy 21 has also been
widely discussed. This may prompt wider investigation of the
coding sequences shared by HSA 21 and CFA 31 and their
significance in disorders resulting from gene dosage abnormalities.
Loss of CFA 11 was identified solely in three of the four
lymphoblastic lymphomas, and represents genetic material shared
with HSA 5 and HSA 9 (Breen et al, 1999a; Yang et al, 1999).
Although these human chromosomes do not appear to represent
regions commonly aberrant in human lymphoma, it is important
to consider that species-specific abnormalities may also play a role
and must be evaluated with equal interest.
In addition to the potential correlation between c-MYC and the
frequent gain of CFA 13 in canine lymphoma, the present report
identifies several other possible evolutionary counterparts of
aberrations found in human NHL. Gain of CFA 1 was noted in
three cases within the present study, including a region
evolutionarily related to HSA 18qdist. Monni et al (1996, 1997)
demonstrated, using CGH analysis, that this human chromosome
region is commonly amplified in several NHL subtypes and can be
directly correlated with aberrant overexpression of a specific
oncogene, BCL2 (HSA 18q21.3), contained within the amplified
chromosome region (HSA 18q21–q23). Gain of material from CFA
35 in two cases may correspond to the common amplification of
HSA 6p in human lymphoma (e.g Monni et al, 1996) as these sites
share an evolutionary origin (Breen et al, 1999a; Yang et al, 1999).
Clearly, cytogenetic analysis of a greater sample size, supported by
Figure 1 Cytogenetic distribution of 41 canine BAC clones representing
a panel of chromosome-specific single locus FISH probes. In this example,
probes are labelled with either Spectrum Red (presented as red signal),
Spectrum Green (presented as green signal), Spectrum Gold (yellow),
DEAC (blue) or biotin-Cy5 (pink). Each canine chromosome can be
identified unequivocally using this panel of probes on the basis of the size of
the chromosome, the cytogenetic location of the BAC clone and the
fluorochrome with which it is labelled.
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to establish whether the observed trends are significant, as well as
the degree to which human and dog lymphoma share a common
genetic aetiology.
A mean number of three chromosome aberrations was detected
in each case. Four cases are notable for a marked increase above
the mean, demonstrating between six and 12 aberrations each. It is
interesting to observe that these represent the four T-cell
lymphomas within the panel of 25 cases. This finding correlates
with previous reports of a higher overall frequency of secondary
chromosome aberrations in human T-cell lymphomas than those
of B-cell origin, with both subtypes appearing to show nonrandom
distribution (Johansson et al, 1995). It is also widely suggested that
B-cell lymphomas typically demonstrate a more favourable
prognosis than T-cell lymphomas. Similarly, Teske et al (1994a)
and others have indicated a tendency towards an extended survival
time and improved overall prognosis in canine B-cell lymphomas
as compared to those of T-cell origin. The challenge for molecular
cytogenetics is in part to establish additional means by which to
subclassify existing broad categories of B- and T-cell lymphoma in
the dog, and ultimately to correlate cytogenetic profiles with
clinical progression and prognosis. We are therefore now pursuing
a larger sample size to determine whether this would continue to
support the tendency of B-cell lymphomas towards fewer
chromosome imbalances, whether subtype-specific aberrations
do exist, and in turn whether the total number of aberrations
detected in each canine lymphoma case can be correlated with
overall prognosis.
Studies of chromosome aberrations in other dog cancers may
also provide support for the significance of specific chromosome
regions in tumorigenesis. As with lymphoma, such studies have
been limited by the poor quality of banding of tumour
chromosome preparations, but certain features can be noted in
common with the present report. Gain of CFA 13 has been
reported in a dog lipoma (Reimann et al, 1999), and gain of CFA 1
in a case of acute leukaemia (Reimann et al, 1998) and of
mammary tumour (Mayr et al, 1996). Gain of both CFA 1 and CFA
13 has also been demonstrated in a canine glial tumour (Dunn et al,
2000). Currently, the number of individuals and of cancer types
studied in each case is insufficient for the assessment of recurrent
aberrations and their significance.
The efficiency of CGH analysis in the domestic dog currently
remains limited by the challenges of efficient and conclusive
chromosome identification throughout the karyotype. Similarly,
although prior studies of karyotypic aberrations in canine
lymphoma (and other cancers) exist, it is difficult to determine
the degree to which they correlate with the findings presented here,
due to the absence of definitive chromosome identification in
previous studies, and the use of different chromosome nomen-
clatures. In order to maintain consistency in (and correlation
between) future reports, we therefore support the continued use of
the standard karyotype nomenclature (Breen et al, 1999b)
endorsed by the canine genome mapping community in the most
recent integrated genome map (Breen et al, 2001). We also propose
the use of the panel of 41 canine single-locus BAC probes
described in this study as an accurate, efficient and universally
available resource for the verification of chromosome identity.
This resource will be key to the continued evaluation of karyotypic
abnormalities in canine malignancies, whether by CGH analysis or
by direct analysis of tumour metaphases.
Figure 2 (A) Detection of unbalanced chromosome aberrations in
canine lymphoma case 4138/00 using CGH analysis. Cohybridisation of
male test (green) and female reference (red) probes onto a normal male
metaphase spread is demonstrated. The sex-mismatch results in a 2:1 ratio
of red:green for the X chromosome, which thus appears red. The Y
chromosome appears green due to the 0:1 ratio of red:green for this
chromosome. A number of autosomes appear to deviate from the
expected 1:1 fluorochrome ratio. The complex microenvironment of the
hybridisation reaction may produce apparent variation in hybridisation
characteristics, as is evident in this cell for the CFA 31 homologues.
However, profiling of 10–15 metaphase preparations serves to neutralise
such differences. (B) Verification of chromosome identity using chromo-
some-specific single-locus probes. In this example, a total of 11
chromosome-specific single-locus probes were cohybridised in two
successive reactions to the metaphase spread shown in (A) to facilitate
accurate chromosome identification for CGH profiling. In the first reaction,
the SLP for CFA 14 and CFA 30 were labelled with DEAC (presented as
blue signal), CFA 26, CFA 28 and CFA 33 were labelled with Spectrum
Orange (presented as green signal) and CFA 20 and CFA 32 were labelled
with biotin-16-dUTP and detected with Cy5 (presented as pink signals).
Following image acquisition, these probes were stripped from the
chromosomes. The slides were then reprobed with a second group of
SLPs, in which CFA 27 and CFA 31 were labelled in Spectrum Orange
(presented as yellow signal) and CFA 25 and CFA 38 were labeled with
DEAC (presented as orange signal). In this figure, the data from the two
successive rounds of FISH have been overlaid to generate a composite
metaphase spread showing all 11 SLPs.
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the present study, the identification of balanced aberrations by
direct cytogenetic evaluation of tumour karyotypes will be an
essential requirement for future work. This will rely heavily upon
the ability to obtain viable tumour material and also to overcome
previously documented limitations in generating high-quality
chromosome preparations from biopsied tumour tissue (e.g.
Carter et al, 1990; Hahn et al, 1994 and others).
A number of limitations are recognised within the present study.
In common with our previous reports of canine CGH analysis
(Dunn et al, 2000; Thomas et al, 2001), we observed intense and
consistent hybridisation signals of both test and reference probes
at the centromeres of a subset of dog chromosomes, reflecting
suboptimal suppression of highly repetitive DNA sequences.
Following conventions in human CGH (e.g. Speicher et al, 1993),
we elected to exclude such sites from analysis. Similarly, we
observed a site of apparently natural polymorphism between
unrelated individuals within CFA 9qprox (Thomas et al, 2001),
which was again excluded due to the risk of detecting false-positive
genome imbalance (Kallioniemi et al, 1994). No other such regions
were identified. Although all biopsy procedures were made at the
time of initial diagnosis, it is not possible from this study to
establish which aberrations represent primary changes involved in
tumour initiation, and which are secondary changes involved in
further progression of the tumour. Sequential sampling and
cytogenetic analysis of a panel of lymphomas from the onset of
hyperplasia onwards would help to elucidate which are the
primary aberrations, but clearly has practical limitations.
The requirements of any CGH study include the need to
generate high-quality metaphase preparations, the ability to
identify each chromosome reliably, the resolution of metaphase-
based technology and the time required to perform the analysis.
We are currently developing a canine CGH genomic microarray,
based on the assembly of a collection of ordered BAC clones that
are dispersed throughout the canine genome at an average interval
of 5Mb. This resource will enable canine CGH analysis to proceed
at a much faster rate and with greater resolution than is currently
possible using conventional methods. Array-based techniques also
enable such studies to be undertaken by laboratories without prior
cytogenetics experience.
Limitations also exist with histopathological analyses of canine
lymphoma, including the absence of a standardised system for
morphological subclassification. We have therefore classified each
case described in the present study using the two most commonly
utilised schemes, enabling ongoing comparison of cytogenetic data
with other parameters discussed in previous studies. As is
common in the histological evaluation of canine lymphoma for
routine diagnosis, immunophenotyping was restricted to the use of
CD3 and CD79a cell markers. The application of more compre-
hensive immunostaining panels for canine lymphoma, as practiced
in humans, may be of value in parallel with cytogenetics in refining
disease classification (reviewed in Mason and Gatter, 1998). The
imminent introduction of the new WHO classification for canine
lymphoma (Parodi, 2001) as an evolution of the REAL system used
in human (Frizzera, 1997) may be advantageous in that respect,
through the incorporation of immunophenotyping data in
Figure 3 Composite of CGH profiles from 25 canine lymphoma cases. The DAPI-banded ideogram of Breen et al (1999a) is displayed. For each case,
genomic gains and losses are shown as green and red bars to the right and left of each chromosome, respectively. Each vertical bar represents a site of
genomic imbalance in a single case (cases are identified at the top or bottom of red/green bars), and demonstrates the physical extent of the chromosome
over which the aberration was detected. The evolutionarily conserved chromosome segments shared with the human karyotype (taken from Breen et al,
2001) are identified with coloured bars to the far left of each chromosome.
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sclassification, in addition to simplification of the morphological
subtypes recognised. Retrospective and prospective analysis of
lymphoma series with the newer classification systems will be
necessary to establish their worth in the dog, and to establish the
degree of comparability between canine and human lymphoma.
This study highlights the recurring nature of cytogenetic
aberrations associated with canine lymphoma and suggests several
trends, both within the canine disease and in comparison with its
human counterpart, that are clearly worthy of continued
investigation. It now becomes imperative to develop means by
which to perform similar analyses on a greater sample size, and to
integrate these findings with those from direct cytogenetic
evaluation of tumour karyotypes. This combined approach will
enable us to determine definitively the relative frequency and
identity of both balanced and unbalanced chromosome aberra-
tions present in canine lymphoma, and to investigate their clinical
relevance. By establishing the degree to which these cytogenetic
abnormalities correlate with the human counterpart of the disease,
we may also establish how readily diagnostic and prognostic
indicators identified in one species may be applied to the
other, and may ultimately lead to a greater understanding of
the precise genetic events involved in tumour initiation and
development.
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